-
1Academic Journal
Authors: S. Z. Safina, A. Z. Isyangulova, С. З. Сафина, А. З. Исянгулова
Source: Cancer Urology; Том 19, № 2 (2023); 94-100 ; Онкоурология; Том 19, № 2 (2023); 94-100 ; 1996-1812 ; 1726-9776
Subject Terms: гормонорезистентность, castration-resistant cancer, prostate, hormone resistance, кастрационно-резистентный рак, предстательная железа
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/1618/1462; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1618/1200; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1618/1201; Злокачественные новообразования в России в 2020 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2021. 252 с.; Aggarwal R., Zhang T., Small E.J., Armstrong A.J. Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes. J Natl Compr Canc Netw 2014;12(5):719–26. DOI:10.6004/jnccn.2014.0073; Nagtegaal I.D., Odze R.D., Klimstra D. et al. The 2019 WHO classification of tumours of the digestive system. Histopathology 2020;76(2):182–8. DOI:10.1111/его.13975; Zhang Q., Han Y., Zhang Y. et al. Treatment-emergent neuroendocrine prostate cancer: a clinicopathological and immunohistochemical analysis of 94 cases. Front Oncol 2021;10:571308. DOI:10.3389/fonc.2020.571308; Hirano D., Okada Y., Minei S. et al. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 2004;45(5):586–92. DOI:10.1016/j.eururo.2003.11.032; Aggarwal R., Huang J., Alumkal J.J. et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J Clin Oncol 2018;36(24):2492–503. DOI:10.1200/JCO.2017.77.6880; Abida W., Cyrta J., Heller G. et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci USA 2019;116(23):11428–36. DOI:10.1073/pnas.1902651116; Bluemn E.G., Coleman I.M., Lucas J.M. et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell 2017;32(4):474–89. DOI:10.1016/j.ccell.2017.09.003; Beltran H., Prandi D., Mosquera J.M. et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med 2016;22(3):298–305. DOI:10.1038/nm.4045; Umar S.A., Maclenna G.T. Small cell carcinoma of the prostate. J Urol 2009;181(2):838–9. DOI:10.1038/nrurol.2014.21; Barcons L.A.L. Small cell neuroendocrine carcinoma of the prostate: are heterotransplants a better experimental model? Asian J Androl 2010;12(3):308–14. DOI:10.1038/aja.2009.68; Beltran H., Tagawa S.T., Park K. et al. Challenges in recognizing treatment-related neuroendocrine prostate cancer. Clin Oncol 2012;30(36):386–9. DOI:10.1200/JCO.2011.41.5166; Beltran H., Rickman D.S., Park K. et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 2011;1(6):487–95. DOI:10.1158/2159-8290.CD-11-0130; Hu C.D., Choo R., Huang J. Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure. Front Oncol 2015;5:90. DOI:10.3389/fonc.2015.00090; Patel G.K., Chugh N., Tripathi M. Neuroendocrine differentiation of prostate cancer-an intriguing example of tumor evolution at play. Cancers (Basel) 2019;11(10):1405. DOI:10.3390/cancers11101405; Аничков Н.М., Плотникова Н.А. О морфологии и классификации опухолеподобных поражений и pака предстательной железы. Архив патологии 2001;(5):44–50.; Zhang Y., Zheng D., Zhou T. et al. Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREBEZH2-TSP1 pathway in prostate cancers. Nat Commun 2018;9(1):4080. DOI:10.1038/s41467-018-06177-2; Puca L., Vlachostergios P.J., Beltran H. Neuroendocrine differentiation in prostate cancer: emerging biology, models, and therapies. Cold Spring Harb Perspect Med 2019;9(2):30593. DOI:10.1101/cshperspect.a030593; Montironi R., Cimadamore A., Lopez-Beltran A. et al. Morphologic, molecular and clinical features of aggressive variant prostate cancer. Cells 2020;9(5):1073. DOI:10.3390/cells9051073; Mahal B.A., Yang D.D., Wang N.Q. et al. Clinical and genomic characterization of low-prostate-specific antigen, high-grade prostate cancer. Eur Urol 2018;74(2):146–54. DOI:10.1016/j.eururo.2018.01.043; Wang J., Xu W., Mierxiati A. et al. Low-serum prostate-specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer. Prostate 2019;79(13):1563–71. DOI:10.1002/pros.23878; Helpap B., Kollermann J., Oehler U. Neuroendocrine differentiation in prostatic carcinomas: histogenesis, biology, clinical relevance, and future therapeutical perspectives. Urol Int 1999;62:133–8. DOI:10.1159/000030376; Marcus D.M., Goodman M., Jani A.B. et al. A comprehensive review of incidence and survival in patients with rare histological variants of prostate cancer in the United States from 1973 to 2008. Prostate Cancer Prostatic Dis 2012;15(3):283–8. DOI:10.1038/pcan.2012.4; Shimamura T., Kurauchi T., Sakanaka K. et al. Clinical investigation of neuroendocrine differentiation in prostate cancer. J Clin Oncol 2020;38:138. DOI:10.1200/jco.2020.38.6_suppl.138; Hvamstad T., Jordal A., Hekmat N. et al. Neuroendocrine serum tumour markers in hormone-resistant prostate cancer. Eur Urol 2003;44(2):215–6. DOI:10.1016/s0302-2838(03)00257-4; Spetsieris N., Boukovala M., Patsakis G. et al. Neuroendocrine and aggressive-variant prostate cancer. Cancers (Basel) 2020;12(12):3792. DOI:10.3390/cancers12123792; Apostolidis L., Nientiedt C., Winkler E.C. et al. Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate. Oncotarget 2019;10(1):17–29. DOI:10.18632/oncotarget.26523; Zhu J., Liang X., Wu D. et al. Clinicopathological characteristics and survival outcomes in neuroendocrine prostate cancer: a population-based study. Medicine (Baltimore) 2021;100(15):25237. DOI:10.1097/MD.0000000000025237; Vlachostergios P.J., Papandreou C.N. Targeting neuroendocrine prostate cancer: molecular and clinical perspectives. Front Oncol 2015;5:6. DOI:10.3389/fonc.2015.00006; Papandreou C.N., Daliani D.D., Thall P.F. et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 2002;20(14):3072–80. DOI:10.1200/JCO.2002.12.065; Culine S., El Demery M., Lamy P.J. et al. Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J Urol 2007;178:844–8. DOI:10.1016/j.juro.2007.05.044; Apostolidis L., Bergmann F., Jäger D., Winkler E.C. Efficacy of topotecan in pretreated metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma. Cancer Med 2016;5(9):2261–7. DOI:10.1002/cam4.807; Antonia S.J., Lopez-Martin J.A., Bendell J. et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 2016;17(70):883–95. DOI:10.1016/S1470-2045(16)30098-5; Kaufman H.L., Russell J., Hamid O. et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 2016;17(10):1374–85. DOI:10.1016/S1470-2045(16)30364-3; Nghiem P.T., Bhatia S., Lipson E.J. et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med 2016;374(26):2542–52. DOI:10.1056/NEJMoa1603702; Ugwu J.K., Nwanyanwu C., Shelke A.R. Dramatic response of a metastatic primary small-cell carcinoma of the pancreas to a trial of immunotherapy with nivolumab: a case report. Case Rep Oncol 2017;10(2):720–5. DOI:10.1159/000479315; Paraghamian S.E., Longoria T.C., Eskander R.N. Metastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report. Gynecol Oncol Res Pract 2017;4:3. DOI:10.1186/s40661-017-0038-9; Conteduca V., Oromendia C., Eng K.W. et al. Clinical features of neuroendocrine prostate cancer. Eur J Cancer 2019;121:7–18. DOI:10.1016/j.ejca.2019.08.011; Wang Z.A., Toivanen R., Bergren S.K. et al. Luminal cells are favored as the cell of origin for prostate cancer. Cell Rep 2014;8(5):1339–46. DOI:10.1016/j.celrep.2014.08.002; Mosca A., Berruti A., Russo L. et al. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects. J Endocrinol Invest 2005;28(11 Suppl):141–5.; Komiya A., Suzuki H., Imamoto T. et al. Neuroendocrine differentiation in the progression of prostate cancer. Int J Urol 2009:6(2):37–44. DOI:10.1111/j.1442-2042.2008.02175.x; https://oncourology.abvpress.ru/oncur/article/view/1618
-
2Academic Journal
Source: Meditsinskiy sovet = Medical Council; № 12 (2022); 173-177 ; Медицинский Совет; № 12 (2022); 173-177 ; 2658-5790 ; 2079-701X
Subject Terms: сакроилеит, tocilizumab, hormone resistance, TNF inhibitor, trauma, тоцилизумаб, гормонорезистентность, ингибитор ФНО, травма
File Description: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/6994/6293; Cassidy J.T., Petty R.E. Chronic arthritis in childhood. In: Cassidy J.T. Textbook of Pediatric Rheumatology. 6th ed. Philadelphia: W.B. Saunders; 2005. pp. 206-260. https://doi.org/10.1016/B978-1-4160-0246-8.50015-2.; Алексеева Е.И., Литвицкий П.Ф., Баранова A.A. (ред.) Ювенильный ревматоидный артрит: этиология, патогенез, клиника, алгоритмы диагностики и лечения. М.: Веди; 2007. 360 c.; Алексеева Е.И., Ломакина О.Л., Валиева С.И., Бзарова Т.М. Обзор международных регистров пациентов с системным ювенильным идиопатическим артритом. Вопросы современной педиатрии. 2017;16(1):18-23. https://doi.org/10.15690/vsp.v16i1.1690.; Modesto C., Anton J., Rodriguez B., Bou R., Arnal C., Ros J. et al. Incidence and prevalence of juvenile idiopathic arthritis in Catalonia (Spain). Scand J Rheumatol. 2010;39(6):472-479. https://doi.org/10.3109/03009741003742722.; Haibel H., Rudwaleit M., Listing J., Heldmann F., Wong R.L., Kupper H. et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum. 2008;58(7):1981-1991. https://doi.org/10.1002/art.23606.; Reiff А. Treatment of systemic juvenile idiopathic arthritis with tocilizum-ab - the role of anti-interleukin-6 therapy after a decade of treatment. Biol Therapy. 2012;2(1):1. https://doi.org/10.1007/s13554-012-0001-6.; Veldhuis G.J., Willemse P.H., Sleijfer D.T., van der Graaf W.T., Groen H.J., Limburg P.C. et al. Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small-cell lung cancer. J Clin Oncol. 1995;13(10):2585-2593. https://doi.org/10.1200/JCO.1995.13.10.2585.; Rothwell N.J., Busbridge N.J., Lefeuvre R.A., Hardwick A.J., Gauldie J., Hopkins S.J. Interleukin-6 is a centrally acting endogenous pyrogen in the rat. Can J Physiol Pharmacol. 1991;69(10):1465-1469. https://doi.org/10.1139/y91-219.; Castell J.V., Gomez-Lechon MJ., David M., Hirano T., Kishimoto T., Heinrich P.C. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett. 1988;232(2):347-350. https://doi.org/10.1016/0014-5793(88)80766-x.; Nemeth E., Rivera S., Gabayan V., Keller C., Taudorf S., Pedersen B.K., Ganz T. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113(9):1271-1276. https://doi.org/10.1172/JCI20945.; Ikebuchi K., Wong G.G., Clark S.C., Ihle J.N., Hirai Y., Ogawa M. Interleukin-6 enhancement of interleukin-3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci USA. 1987;84(24):9035-9039. https://doi.org/10.1073/pnas.84.24.9035.; Kimura H., Ishibashi T., Uchida T., Maruyama Y., Friese P., Burstein S.A. Interleukin 6 is a differentiation factor for human megakaryocytes in vitro. Eur J Immunol. 1990;20(9):1927-1931. https://doi.org/10.1002/eji.1830200909.; Tsigos C., Papanicolaou D.A., Defensor R., Mitsiadis C.S., Kyrou I., Chrousos G.P. Dose effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure. Neuroendocrinology. 1997;66(1):54-62. https://doi.org/10.1159/000127219.; Heliovaara M.K., Teppo A.-M., Karonen S.L., Tuominen J.A., Ebeling P. Plasma IL-6 concentration is inversely related to insulin sensitivity, and acutephase proteins associate with glucose and lipid metabolism in healthy subjects. Diabetes Obes Metab. 2005;7(6):729-736. https://doi.org/10.1111/j.1463-1326.2004.00463.x.; Cutolo M., Straub R.H. Circadian rhythms in arthritis: hormonal effects on the immune/inflammatory reaction. Autoimmun Rev. 2008;7(3):223-228. https://doi.org/10.1016/j.autrev.2007.11.019.; Emery P., Sebba A., Huizinga T.W.J. Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. Ann Rheum Dis. 2013;72(12):1897-1904. https://doi.org/10.1136/annrheumdis-2013-203485.; Brunner H.I., Ruperto N., Zuber Z., Keane C., Harari O., Kenwright A. et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, doubleblind withdrawal trial. Ann Rheum Dis. 2015;74(6):1110-1117. https://doi.org/10.1136/annrheumdis-2014-205351.; Никишина И.П., Каледа М.И. Современная фармакотерапия системного ювенильного артрита. Научно- практическая ревматология. 2015;53(1):84-93. https://doi.org/10.14412/1995-4484-2015-84-93.; Карпенко А.А. Роль ранней лучевой диагностики сакроилеитов у детей при синдроме артрита. Лучевая диагностика и терапия. 2017;(2):13-19. Режим доступа: https://radiag.bmoc-spb.ru/jour/article/view/212/0.; Жолобова Е.С., Лоскутова О.Ю., Галстян Л.А., Серая В.А., Николаев М.Н., Афонина Е.Ю. и др. Оценка эффективности и безопасности генноинженерных биологических препаратов (инфликсимаба, этанерцепта, абатацепта) у детей. Педиатрия. Журнал имени Г.Н. Сперанского. 2017;96(3):79-85. https://doi.org/10.24110/0031-403X-2017-96-3-79-85.; Санталова Г.В., Бородулина Е.А., Бородулин Б.Е., Кудлай Д.А., Ураксина М.В., Амосова Е.А. Сложности подбора терапии у пациента с тяжелым течением пауциартикулярного варианта юношеского артрита, ассоциированного с HLA-B27 антигеном. Педиатрия. Журнал имени Г.Н. Сперанского. 2020;99(5):244-249. Режим доступа: https://pediatriajournal.ru/archive?show=378§ion=6036.; Beukelman T., Patkar N.M., Saag K.G., Tolleson-Rinehart S., Cron R.Q., DeWitt E.M. et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken). 2011;63(4):465-482. https://doi.org/10.1002/acr.20460.; Lovell D.J., Reiff A., Ilowite N.T., Wallace C.A., Chon Y., Lin S.L. et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008;58(5):1496-1504. https://doi.org/10.1002/art.23427.; Avau A., Put K., Wouters C.H., Matthys P. Cytokine balance and cytokine-driven natural killer cell dysfunction in systemic juvenile idiopathic arthritis. Cytokine Growth Factor Rev. 2015;26(1):35-45. https://doi.org/10.1016/j.cytogfr.2014.05.005.; Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003;374(1):1-20. https://doi.org/10.1042/BJ20030407.; Rose-John S. Interleukin-6 Family Cytokines. Cold Spring Harb Perspect Biol. 2018;10(2):a028415. https://doi.org/10.1101/cshperspect.a028415.; Панкратов А.С., Ардатов С.В., Огурцов Д.А., Ким Ю.Д., Шитиков Д.С., Шитиков Д.С. Новый подход к решению проблемы комплексного регионарного болевого синдрома. Наука и инновации в медицине. 2017;2(3):32-38. https://doi.org/10.35693/2500-1388-2017-0-3-32-38.; Nishimoto N., Kishimoto T. Humanized antihuman IL-6 receptor antibody, tocilizumab. Handb Exp Pharmacol. 2008;(181):151-160. https://doi.org/10.1007/978-3-540-73259-4_7.; Schoels M.M., van der Heijde D., Breedveld F.C., Burmester G.R., Dougados M., Emery P. et al. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement Ann Rheum Dis. 2013;72(4):583-589. https://doi.org/10.1136/annrheum-dis-2012-202470.
-
3Academic Journal
Authors: A. A. Kostin, A. G. Muradyan, A. O. Tolkachev, S. V. Popov, А. А. Костин, А. Г. Мурадян, А. О. Толкачев, С. В. Попов
Contributors: BAYER, JSC, АО БАЙЕР
Source: Research and Practical Medicine Journal; Том 4, № 4 (2017); 79-88 ; Research'n Practical Medicine Journal; Том 4, № 4 (2017); 79-88 ; 2410-1893 ; 10.17709/2409-2231-2017-4-4
Subject Terms: гормонорезистентность, PC, castration-refractory, mCRPC, radium-223, Ksofigo, hormoneresistence, РПЖ, кастрационно-рефрактерный, мКРРПЖ, радий-223, Ксофиго®
File Description: application/pdf
Relation: https://www.rpmj.ru/rpmj/article/view/223/210; Каприн А. Д., Старинский В. В., Петрова Г. В. Злокачественные новообразования в России в 2016 году (заболеваемость и смертность). М.: МНИОИ им. П. А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018, 250 с. Доступно по: http://www.oncology.ru/service/statistics/malignant_tumors/2016.pdf; Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136 (5): E359–86. DOI:10.1002/ijc.29210.; Gupta N, Devgan A, Bansal I, Olsavsky TD, Li S, Abdelbaki A, Kumar Y. Usefulness of radium-223 in patients with bone metastases. Proc (Bayl Univ Med Cent). 2017 Oct;30 (4):424–426. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595381/; Bubendorf L, Schöpfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000 May;31 (5):578–83.; Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008 Mar 1;26 (7):1148–59. DOI:10.1200/JCO.2007.12.4487; Taylor CD, Elson P, Trump DL. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol. 1993 Nov;11 (11):2167–72. DOI:10.1200/JCO.1993.11.11.2167; Beer TM, Tombal B. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy. N Engl J Med. 2014 Oct 30;371 (18):1755–6. DOI:10.1056/NEJMc1410239.; Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COUAA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012 Oct;13 (10):983–92. DOI:10.1016/S1470–2045(12)70379–0; Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015 Feb;16 (2):152–60. DOI:10.1016/S1470–2045(14)71205–7; Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008 Jan 10;26 (2):242–5. DOI:10.1200/JCO.2007.12.4008; de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010 Oct 2;376 (9747):1147–54. DOI:10.1016/S0140–6736 (10)61389-X; Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer. N Engl J Med. 2004 Oct 7;351 (15):1502–12. DOI:10.1056/NEJMoa040720; Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. N Engl J Med. 2010 Jul 29;363 (5):411–22. DOI:10.1056/NEJMoa1001294.; Ibrahim T, Flamini E, Mercatali L, Sacanna E, Serra P, Amadori D. Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer. 2010 Mar 15;116 (6):1406–18. DOI:10.1002/cncr.24896; Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer. 2005 Jan;5 (1):21–8. DOI:10.1038/nrc1528; Festuccia C, Giunciuglio D, Guerra F, Villanova I, Angelucci A, Manduca P, et al. Osteoblasts modulate secretion of urokinase-type plasminogen activator (uPA) and matrix metalloproteinase-9 (MMP-9) in human prostate cancer cells promoting migration and matrigel invasion. Oncol Res. 1999;11 (1):17–31.; Armstrong AP, Miller RE, Jones JC, Zhang J, Keller ET, Dougall WC. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate. 2008 Jan 1;68 (1):92–104. DOI:10.1002/pros.20678; Suominen MI, Fagerlund KM, Rissanen JP, Konkol YM, Morko JP, Peng Z, et al. Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models. Clin Cancer Res. 2017 Aug 1;23 (15):4335–4346. DOI:10.1158/1078–0432.CCR-16–2955; Dauer LT, Williamson MJ, Humm J, O’Donoghue J, Ghani R, Awadallah R, et al. Radiation safety considerations for the use of 223RaCl₂ DE in men with castration-resistant prostate cancer. Health Phys. 2014 Apr;106 (4):494–504. DOI:10.1097/HP.0b013e3182a82b37.; Bruland OS, Nilsson S, Fisher DR, Larsen RH. High-Linear Energy Transfer Irradiation Targeted to Skeletal Metastases by the -Emitter 223Ra: Adjuvant or Alternative to Conventional Modalities? Clin Cancer Res. 2006 Oct 15;12 (20 Pt 2):6250s-6257s. DOI:10.1158/1078–0432.CCR-06–0841; File: Alfa beta gamma radiation penetration-RUS.svg — Wikimedia Commons [Internet]. URL: https://commons.wikimedia.org/wiki/File: Alfa_beta_gamma_radiation_penetration-RUS.svg (accessed 18.09.2017).; Nilsson S, Larsen RH, Fosså SD, Balteskard L, Borch KW, Westlin JE, et al. First Clinical Experience with -Emitting Radium-223 in the Treatment of Skeletal Metastases. Clin Cancer Res. 2005 Jun 15;11 (12):4451–9. DOI:10.1158/1078–0432.CCR-04–2244; Nilsson S, Franzén L, Parker C, Tyrrell C, Blom R, Tennvall J, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007 Jul;8 (7):587–94. DOI:10.1016/S1470–2045(07)70147-X; Nilsson S, Strang P, Aksnes AK, Franzèn L, Olivier P, Pecking A, et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer. 2012 Mar;48 (5):678–86. DOI:10.1016/j.ejca.2011.12.023; Parker CC, Pascoe S, Chodacki A, O’Sullivan JM, Germá JR, O’Bryan-Tear CG, et al. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol. 2013 Feb;63 (2):189–97. DOI:10.1016/j.eururo.2012.09.008; Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, et al. Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer. N Engl J Med. 2013 Jul 18;369 (3):213–23. DOI:10.1056/NEJMoa1213755; Sartor O, Hoskin P, Coleman RE, Nilsson S, Vogelzang NJ, Petrenciuc O, et al. Chemotherapy following radium-223 dichloride treatment in ALSYMPCA. Prostate. 2016 Jul;76 (10):905–16. DOI:10.1002/pros.23180; https://www.rpmj.ru/rpmj/article/view/223
-
4Academic Journal
Authors: Костецкая, Т.В., Лемешевский, В.О., Батян, А.Н., Kasteсkayа, T., Lemiasheuski, V., Batyan, A.
Subject Terms: рак молочной железы, гормонотерапия, гормонорезистентность, тамоксифен, ингибиторы ароматазы, овариосупрессия, breast cancer, hormone therapy, hormone resistance, tamoxifen, aromatase inhibitors, ovariosuppression
File Description: application/pdf
Availability: https://rep.polessu.by/handle/123456789/32069
-
5Academic Journal
Authors: Березин, Петр, Милованов, Владимир, Иванников, Андрей
Subject Terms: КАСТРАЦИОННО-РЕФРАКТЕРНЫЙ РАК ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ, АНАЛОГИ СОМАТОСТАТИНА, ОКТРЕОТИД, ПЕРВИЧНАЯ ГОРМОНОРЕЗИСТЕНТНОСТЬ
File Description: text/html
-
6Academic Journal
Authors: O. B. Karyakin, О. Б. Карякин
Source: Cancer Urology; Том 7, № 1 (2011); 101-106 ; Онкоурология; Том 7, № 1 (2011); 101-106 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2011-7-1
Subject Terms: медиана выживаемости, hormone resistance, chemotherapy, docetaxel, prostate-specific antigen level, median survival, гормонорезистентность, химиотерапия, доцетаксел, уровень простатспецифического антигена
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/120/136; Tannock I.F., de Wit R., Berry W.R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.; N Engl J Med 2004;351:1502–12.; Petrylak D.P., Tangen C.M., Hussain M.H. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513–20.; Bellmunt J. Role of chemotherapy in nonmetastatic hormone-refractory prostate cancer. Eur Urol 2009;8(Suppl):448–52.; Berthold D.R., Pond G.R., Soban F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26:242–5.; Berthold D.R., Pond G.R., Roessner M. et al. Treatment of hormonerefractory prostate cancer with docetaxel or mitoxantrone: relationship between prostatespecific antigen, pain and quality of life response and survival in the TAX 327 study. Clin Cancer Res 2008;14(9):2763–7.; Armstrong A.J., Garrett-Mayer E.S., Yang Y.C. et al. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX 327 study analysis. Clin Cancer Res 2007;13:6396–403.; Oudard S., Banu E., Medioni J. et al. What is the real impact of bone pain on survival of hormone-refractory prostate cancer (HRPC) patients treated with docetaxel? J Clin Oncol 2007;25(Suppl):5149.; Oudard S., Banu E., Scotte F. et al. Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. Ann Oncol 2007;18:1828–33.; Petrylak D.P., Ankerst D.P., Jiang C.S. et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 2006;98:516–21.; Hussain M., Goldman B., Tangen С. Use of prostate specific antigen progression (PSA-P) to predict overall survival (OS) in patients (pts) with metastatic prostate cancer: data from S9346 and S9916. J Clin Oncol 2008;26(Suppl):5015.; Michels J.E., Montemurro T., Murray N. et al. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer (HRPC): does sequence matter? Cancer 2006;106:1041–6.; Oh W.K., Manola J., Babcic V. et al. Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. Urology 2006;67:1235–40.; Berthold D.R., Pond G., de Witt R. et al., TAX 327 Investigators. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 2008;19:1749–53.; Eymard J.C., Oudard S., Gravis G., Ferrero J.M. et al. Docetaxel reintroduction in patients with metastatic castrationresistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. BJU Int 2010;1–5.; Gernone A., Troccoli G., Pagliarulo V., Pagliarulo A. Retreatment with Docetaxel in metastatic castration-resistant prostate cancer (CRPC). Genitourinary Cancers Symposium, ASCO, San Francisco, SA USA, March 05–07, 2010; abstr 143.; Firek P., Pfister D.A., Thiier D. et al. Docetaxel rechallenge at PSA relapse after Docetaxel chemotherapy at hormonerefractory prostate cancer. Genitourinary Cancers Symposium, ASCO, San Francisco SA, USA, March 05–07, 2010; abstr 93.; Ansari J., Choo B., Hussain S.A. et al. Docetaxel retreatment as second- and thirdline chemotherapy in metastatic hormone refractory prostate cancer patients pretreated with docetaxel: An updated analysis. Genitourinary Cancers Symposium, ASCO, Orlando, FL, February 26–28, 2009; abstr 185.; Epplen R., Pfister D.J., Thiier D. et al. The combination of Docetaxel and Bevazizumab as a second-line therapy in patients with HRPCA and PSA relapse. Genitourinary Cancers Symposium, ASCO, San Francisco SA, USA, March 05–07, 2010; abstr 97.; Heidenreich A., Pfister D.A., Thiier D. et al. Docetaxel rechallenge versus Docetaxel/Bevacizumab in castrationresistant prostate cancer following firstline Docetaxel. Genitourinary Cancers Symposium, ASCO, San Francisco SA, USA, March 05–07, 2010; abstr 178.; Caffo O., Sava T., Comploj E. et al. Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone. Urol Oncol 2010;28:152–6.; Sartor O., Oudard S., Ozguroglu M. et al. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC). Genitourinary Cancers Symposium, ASCO, San Francisco SA, USA, March 05–07, 2010; abstr 9.; Heidenreich A., Bolla M., Joniau S. et al. EAU guidelines on prostate cancer 2010. http://www.uroweb.org/guidelines/online-guidelines/; https://oncourology.abvpress.ru/oncur/article/view/120
-
7Academic Journal
Authors: Хрущева, Н. А., Пономарева, Н. В., Сафронова, Л. Е., Тузанкина, И. А., Валамина, И. Е., Строкова, Н. Д., Хаймин, В. М.
Subject Terms: САНДИММУН НЕОРАЛ, НЕФРОТИЧЕСКИЙ СИНДРОМ, ГОРМОНОЧУВСТВИТЕЛЬНОСТЬ, ГОРМОНОРЕЗИСТЕНТНОСТЬ, ГЛОМЕРУЛОНЕФРИТ
File Description: application/pdf
Relation: Уральский медицинский журнал. 2007. Т. 37, № 9.; http://elib.usma.ru/handle/usma/17425
Availability: http://elib.usma.ru/handle/usma/17425
-
8Academic Journal
Authors: Игнатова, Майя, Харина, Е., Курбанова, Э., Обухова, В., Коровина, Н., Литвак, М., Хрущева, Н., Маковецкая, Г., Соболева, М., Канатбаева, А.
Subject Terms: САНДИММУН-НЕОРАЛ, НЕФРОТИЧЕСКИЙ СИНДРОМ, ГОРМОНОЧУВСТВИТЕЛЬНОСТЬ, ГОРМОНОРЕЗИСТЕНТНОСТЬ, ГЛОМЕРУЛОНЕФРИТ, ДЕТИ
File Description: text/html
-
9Academic Journal
Source: Вестник Тамбовского университета. Серия: Естественные и технические науки.
Subject Terms: КАСТРАЦИОННО-РЕФРАКТЕРНЫЙ РАК ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ, АНАЛОГИ СОМАТОСТАТИНА, ОКТРЕОТИД, ПЕРВИЧНАЯ ГОРМОНОРЕЗИСТЕНТНОСТЬ, 0101 mathematics, 01 natural sciences, 3. Good health
File Description: text/html
-
10Academic Journal
Source: Медицинский вестник Башкортостана.
Subject Terms: РАК ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ, ДОБРОКАЧЕСТВЕННАЯ ГИПЕРПЛАЗИЯ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ, ЭНДОКРИННЫЕ КЛЕТКИ, ГОРМОНОРЕЗИСТЕНТНОСТЬ, 3. Good health
File Description: text/html
-
11Academic Journal
Source: Педиатрическая фармакология.
Subject Terms: 3. Good health, САНДИММУН-НЕОРАЛ, НЕФРОТИЧЕСКИЙ СИНДРОМ, ГОРМОНОЧУВСТВИТЕЛЬНОСТЬ, ГОРМОНОРЕЗИСТЕНТНОСТЬ, ГЛОМЕРУЛОНЕФРИТ, ДЕТИ
File Description: text/html
